Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biopharmx Corp stock logo
BPMX
Biopharmx
$0.00
$0.25
$6.30
$111.86MN/A2.15 million shs336,508 shs
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
C$0.45
-1.1%
C$0.43
C$0.35
C$0.66
C$50.08M0.8265,969 shs110,700 shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biopharmx Corp stock logo
BPMX
Biopharmx
0.00%0.00%0.00%0.00%0.00%
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
-1.11%+21.92%+14.10%+11.25%-29.37%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/AN/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
C$25.87M1.94C$0.05 per share8.93C$0.25 per share1.78

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
-C$16.96M-C$0.17N/AN/A-65.57%-47.87%-15.68%4/25/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
71.36
1.52
1.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Biopharmx Corp stock logo
BPMX
Biopharmx
N/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
0.03%

Insider Ownership

CompanyInsider Ownership
Biopharmx Corp stock logo
BPMX
Biopharmx
N/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
7.11%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Biopharmx Corp stock logo
BPMX
Biopharmx
1718.28 millionN/ANot Optionable
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
249112.54 millionN/ANot Optionable

BPMX and NSCI Headlines

SourceHeadline
Nanalysis Announces Full Year 2023 Conference CallNanalysis Announces Full Year 2023 Conference Call
ca.finance.yahoo.com - April 11 at 10:39 AM
Nanalysis Scientific Corp. Announces Director ResignationNanalysis Scientific Corp. Announces Director Resignation
ca.finance.yahoo.com - April 10 at 10:29 AM
AI Revolutionizes Drug Detection with Compact NMR and Machine LearningAI Revolutionizes Drug Detection with Compact NMR and Machine Learning
theglobeandmail.com - April 4 at 4:36 PM
Scientists identify distinct molecular signatures for sepsis diagnosis and prognosisScientists identify distinct molecular signatures for sepsis diagnosis and prognosis
msn.com - March 31 at 8:59 PM
Insider Buying: Nanalysis Scientific Corp. (CVE:NSCI) Director Acquires 80,000 Shares of StockInsider Buying: Nanalysis Scientific Corp. (CVE:NSCI) Director Acquires 80,000 Shares of Stock
insidertrades.com - March 19 at 5:39 AM
Canadian Investment Regulatory Organization Trading Halt - NSCICanadian Investment Regulatory Organization Trading Halt - NSCI
ca.finance.yahoo.com - March 6 at 6:23 PM
Canadian Investment Regulatory Organization Trade Resumption - NSCICanadian Investment Regulatory Organization Trade Resumption - NSCI
finance.yahoo.com - March 6 at 6:23 PM
Nanalysis Scientific Corp.: Nanalysis Achieves Record Revenue in Q4Nanalysis Scientific Corp.: Nanalysis Achieves Record Revenue in Q4
finanznachrichten.de - February 6 at 1:27 PM
Nanalysis Scientific says Q4 revenue expected to be at least $9.3MNanalysis Scientific says Q4 revenue expected to be at least $9.3M
msn.com - February 6 at 1:27 PM
Nanalysis Achieves Record Revenue in Q4Nanalysis Achieves Record Revenue in Q4
finance.yahoo.com - February 6 at 9:43 AM
Nanalysis Scientific Corp. Provides Update on Security Services BusinessNanalysis Scientific Corp. Provides Update on Security Services Business
finance.yahoo.com - January 30 at 8:55 AM
Closing Bell: Nanalysis Scientific Corp flat on Thursday (NSCI)Closing Bell: Nanalysis Scientific Corp flat on Thursday (NSCI)
theglobeandmail.com - December 15 at 9:47 AM
Nanalysis Scientific Corp Ordinary Shares NSCINanalysis Scientific Corp Ordinary Shares NSCI
morningstar.com - December 2 at 2:33 PM
Nanalysis Scientific Corp.: Nanalysis Reports Third Quarter 2023 ResultsNanalysis Scientific Corp.: Nanalysis Reports Third Quarter 2023 Results
finanznachrichten.de - December 1 at 3:28 PM
Nanalysis Reports Third Quarter 2023 ResultsNanalysis Reports Third Quarter 2023 Results
finance.yahoo.com - November 29 at 7:47 PM
Nanalysis Announces Third Quarter 2023 Conference CallNanalysis Announces Third Quarter 2023 Conference Call
finance.yahoo.com - November 15 at 9:51 AM
Nanalysis Scientific Corp. (NSCIF)Nanalysis Scientific Corp. (NSCIF)
finance.yahoo.com - November 2 at 7:39 AM
Nanalysis Scientific: Top 10 Undervalued Hardware Industry Stocks (NSCI)Nanalysis Scientific: Top 10 Undervalued Hardware Industry Stocks (NSCI)
theglobeandmail.com - October 29 at 5:51 PM
Stories by Chelsea HarveyStories by Chelsea Harvey
scientificamerican.com - October 24 at 1:27 PM
Nanalysis Scientific Corp.s (CVE:NSCI) Share Price Is Matching Sentiment Around Its RevenuesNanalysis Scientific Corp.'s (CVE:NSCI) Share Price Is Matching Sentiment Around Its Revenues
finance.yahoo.com - September 11 at 11:07 AM
Nanalysis Scientific Corp.: Nanalysis Reports Second Quarter 2023 ResultsNanalysis Scientific Corp.: Nanalysis Reports Second Quarter 2023 Results
finanznachrichten.de - August 25 at 6:03 PM
Echelon Wealth Partners Reaffirms Their Buy Rating on Nanalysis Scientific (NSCIF)Echelon Wealth Partners Reaffirms Their Buy Rating on Nanalysis Scientific (NSCIF)
markets.businessinsider.com - August 25 at 8:21 AM
Nanalysis Scientific reports Q2 resultsNanalysis Scientific reports Q2 results
seekingalpha.com - August 24 at 9:24 PM
Nanalysis Reports Second Quarter 2023 ResultsNanalysis Reports Second Quarter 2023 Results
finance.yahoo.com - August 24 at 4:23 PM

Media Sentiment Over Time

Company Descriptions

Biopharmx logo

Biopharmx

NYSEAMERICAN:BPMX
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.
Nanalysis Scientific logo

Nanalysis Scientific

CVE:NSCI
Nanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.